Bispecific monoclonal antibodies that bind a tumor-associated antigen and CD3 on T cells to redirect cytotoxic T-cell activity against malignant cells.
Bispecific monoclonal antibodies that simultaneously bind CD3 on T cells and a tumor-associated antigen on malignant cells, crosslinking T cells to tumor targets to trigger CD3-mediated activation, immunologic synapse formation, and perforin/granzyme-mediated cytotoxic killing.
The bispecific antibody binds GPRC5D on target cells and CD3 on T cells, crosslinking them to form an immunologic synapse and activate T-cell killing via perforin/granzyme-mediated apoptosis.
Afucosylated humanized IgG1 monoclonal antibody targeting IL‑5 receptor alpha (IL‑5Rα) on eosinophils and basophils; blocks IL‑5 signaling and induces ADCC to deplete eosinophils; used for severe eosinophilic asthma (brand: Fasenra).
Afucosylated humanized IgG1 monoclonal antibody against IL-5 receptor alpha on eosinophils and basophils; blocks IL-5 signaling and engages FcγRIIIa to induce potent ADCC, depleting eosinophils and reducing type 2 inflammation in severe eosinophilic asthma.
Benralizumab binds IL-5Rα on eosinophils/basophils and engages FcγRIIIa on NK cells to drive potent antibody-dependent cellular cytotoxicity (ADCC), leading to apoptosis/depletion of IL-5Rα+ cells.
Human IgG1κ anti-CD38 monoclonal antibody (Darzalex) given IV post–allo-HCT after myeloablative TBI; targets CD38 on malignant lymphoblasts, inducing complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity/phagocytosis, and apoptosis, and depletes CD38+ immune subsets.
Human IgG1κ monoclonal antibody targeting CD38; binding to CD38 on tumor and immune cells triggers complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and can induce apoptosis, leading to depletion of CD38-expressing malignant cells and immunosuppressive subsets.
Anti-CD38 IgG1 binds CD38 and induces complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) via Fc-engaged NK cells, antibody-dependent cellular phagocytosis (ADCP) by myeloid cells, and can trigger apoptosis of CD38+ cells.
Anti-CD20 monoclonal antibody that depletes CD20-positive B cells via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and apoptosis.
Chimeric anti-CD20 monoclonal antibody that binds CD20 on B cells and depletes them via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and apoptosis.
Binds CD20 and kills via immune effectors engaged by the antibody: ADCC by FcγR+ NK cells/macrophages, complement-dependent cytotoxicity (C1q activation), and possible direct apoptosis upon CD20 crosslinking.
A trispecific T-cell engager (multispecific antibody biologic) that binds CD3 on T cells and CD19/CD20 on B cells to redirect T-cell cytotoxicity against malignant B cells in relapsed/refractory B-cell non-Hodgkin lymphoma; administered with step-up then maintenance IV or SC dosing on 21-day cycles.
IgG-like trispecific T-cell engager that simultaneously binds CD3 on T cells and CD19/CD20 on B cells, redirecting and activating cytotoxic T cells to kill CD19/CD20-expressing malignant B cells and reducing antigen-escape by dual B-cell targeting.
Trispecific T‑cell engager binds CD3 on T cells and CD19 on target cells, forming an immune synapse that activates T cells to release perforin and granzymes, causing apoptosis/lysis of CD19+ cells.